1Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am-J-Psychiatry, 2004, 161 (4) : 612-629.
2Rittmannsberger H. Pachinger T, Keppelmuller P, et al. Medication adherence among psychotic patients before admission to inpatient treatment.Psychiatr-Serv, 2004, 55(2) : 174-179.
3Bebbington PE. The content and context of compliance. Int-Clin-Psychopharmacol, 1995, 9(Suppl. 5): 41 50.
4Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr-Serv, 2001, 52(6): 805-811.
5Thieda P. Beard S, Richter A. et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr-Serv,2003, 54(4): 508-516,.
7Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Aeta Psychiatr-Seand-Suppl, 2000, 102(407) : 83-86.
8Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J-Clin-Psychiatry, 2003, 64 ( 11 ):1308-1315.
8[1]Aitchison K J, Meehan K, Murray RM. First Episode Psychosis[M]. London:Martin Dunitz, 1999:83-107.
9[2]Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables[J]. Int Clin.Psychopharmacol, 1995, 10(Sup 3): 133- 138.
10[3]Misdrahi D, Llorca PM, Lancon C, et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications[J]. Encephale, 2002,28 (3 Pt 1): 266- 272.
